Join Dr. Matt Pratt-Hyatt for an inside look at the next generation of mycotoxin testing and discover how advances in detection can provide greater clinical insight. Explore common sources and symptoms of mycotoxin exposure, while uncovering the science behind KBMO’s advanced approach—including Phase II metabolite detection and quantitative methodologies designed to go beyond traditional testing. Learn how these enhanced insights can help clinicians better understand patient exposure, interpret results with greater confidence, and translate findings into more informed, personalized clinical decisions.